This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Infinity Initiates 2 Studies for Lead Candidate IPI-549
by Zacks Equity Research
Infinity (INFI) initiates two studies for IPI-549 -- a first-in-class, oral immuno-oncology product candidate.
Roche Extends Offer to Acquire Spark Therapeutics Yet Again
by Zacks Equity Research
Roche's (RHHBY) acquisition of Spark Therapeutics gets delayed once again to allow the FTC more time for review.
Novartis Inks Commercialization Deal for Tysabri Biosimilar
by Zacks Equity Research
Novartis' (NVS) generics unit, Sandoz, inks deal with Polpharma Biologics for a proposed natalizumab biosimilar for the treatment of RRMS.
Top-Performing Biotech ETFs YTD
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to boost the biotech stocks. Accordingly, we take a look at biotech ETFs gaining more than 10% year to date.
The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie
Global Blood Focuses on Lead Candidate Amid Competition
by Zacks Equity Research
Global Blood (GBT) focuses on the development of its lead product candidate, voxelotor - an oral, once-daily treatment for SCD.
5 Cancer-Fighting Stocks to Add to Your Portfolio
by Zacks Equity Research
Cancer-fighting stocks receive a boost from advance research and development. These five stocks can add value to your portfolio.
AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails
by Zacks Equity Research
IDMC recommends termination of AbbVie's (ABBV) late-stage study on its small cell lung cancer candidate, Rova-T. AbbVie discontinues development.
Pharma Stock Roundup: JNJ's Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs
by Kinjel Shah
Oklahoma imposes fine of $572 million on J&J (JNJ). FDA gives nod to Lilly's (LLY) Taltz while EU approves Bristol-Myers' (BMY) Empliciti and Roche's (RHHBY) Tecentriq for expanded patient population.
Roche's Tecentriq Combo Gets EU Nod for Critical Breast Cancer
by Zacks Equity Research
Roche (RHHBY) wins EU approval for its immuno-oncology drug Tecentriq in combination with Abraxane to treat metastatic triple-negative breast cancer, which is a difficult-to-treat disease.
Forget Pfizer, Add These Big Drugmakers to Your Portfolio
by Kinjel Shah
Buy these three large drug companies instead of Pfizer (PFE) as the stock is down this year.
AstraZeneca's Farxiga Gets Fast Track Tag for Renal Outcome
by Zacks Equity Research
The FDA assigns a Fast Track status to AstraZeneca's (AZN) Farxiga to delay progression of renal failure and prevent cardiovascular and renal death in patients with chronic kidney disease.
Amgen Presents Positive Data From Rituxan Biosimilar Study
by Zacks Equity Research
Amgen (AMGN) markets Mvasi and Kanjinti, biosimilar versions of Avastin and Herceptin, respectively in the United States, and Kanjinti and Amgevita, biosimilar of Humira, in the EU.
Roche's Tecentriq Gets Japan's Nod for Small Cell Lung Cancer
by Zacks Equity Research
Roche (RHHBY) gets approval for Tecentriq in Japan for extensive-stage SCLC.
Novo Nordisk's Fiasp Gets EC Approval for Label Expansion
by Zacks Equity Research
Novo Nordisk (NVO) receives EC approval for its fast-acting insulin aspart, Fiasp, for the treatment of diabetes in adolescents and children aged one year or older.
BeiGene's NDA for Zanubrutinib Gets Priority Review From FDA
by Zacks Equity Research
The FDA grants priority review to BeiGene's (BGNE) NDA seeking approval for zanubrutinib as a treatment for mantle cell lymphoma.
Pfizer's Xtandi Label Expansion Filing Gets Priority Review
by Zacks Equity Research
If data from ARCHES study is approved to be included in the label of Pfizer's (PFE) Xtandi, it can treat a broader prostate cancer patient population.
Synlogic Discontinues Development of SYNB1020, Stock Down
by Zacks Equity Research
Synlogic (SYBX) discontinues the development of its early-stage pipeline candidate, SYNB1020, for the treatment of hyperammonemia, following disappointing study results.
Exelixis (EXEL) Stock Up 15.2% YTD on Strong Cabometyx Sales
by Zacks Equity Research
Exelixis (EXEL) continues to fortify its footing in the kidney cancer market on strong Cabometyx performance.
Here's Why Allergan is Outperforming Its Industry Of Late
by Zacks Equity Research
Allergan's (AGN) pending merger with AbbVie, positive pipeline and regulatory updates and increase in sales guidance twice are driving shares up this year.
Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY
by Kinjel Shah
FDA approves Roche's (RHHBY) tumor-agnostic medicine, Rozlytrek, J&J's Sirturo for young TB patients.
AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL
by Zacks Equity Research
The Breakthrough Therapy Designation (BTD) to AstraZeneca's (AZN) Calquence is based on positive interim data from two phase III studies.
Roche Receives FDA Nod for Rozlytrek in ROS1-positive NSCLC
by Zacks Equity Research
Roche's (RHHBY) lung cancer portfolio gets a boost with the approval of yet another drug, Rozlytrek, for metastatic NSCLC.
Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat
by Zacks Equity Research
Epizyme (EPZM) aims at developing its lead pipeline candidate, tazemetostat, which is under FDA review with an action date of Jan 23, 2020.
Accenture (ACN) to Acquire INSITUM to Boost Interactive Suite
by Zacks Equity Research
The buyout is expected to expand Accenture's (ACN) position as one of the leading experience agencies in the rapidly growing Latin American market.